NCT04883814 is a Phase 2 clinical trial of 18F-fluoroestradiol PET/CT in Breast Cancer, sponsored by Hoag Memorial Hospital Presbyterian.

Who is sponsoring NCT04883814?

NCT04883814 is sponsored by Hoag Memorial Hospital Presbyterian.

What drugs are being tested in NCT04883814?

Interventions in NCT04883814: 18F-fluoroestradiol PET/CT.

What condition does NCT04883814 study?

NCT04883814 studies Breast Cancer.

Is NCT04883814 still recruiting?

NCT04883814 is currently status unknown. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT04883814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-fluoroestradiol (FES) PET/CT for Breast Cancer

Status unknown Phase 2 Last updated 28 September 2023

What this trial tests

Phase 2 trial testing 18F-fluoroestradiol PET/CT in Breast Cancer in 124 participants. Status unknown.

Timeline

15 January 2021

Primary endpoint
15 December 2023

15 December 2023

Quick facts

Lead sponsor	Hoag Memorial Hospital Presbyterian
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	124
Start date	15 January 2021
Primary completion	15 December 2023
Estimated completion	15 December 2023
Sites	1 location across United States

Drugs / interventions tested

18F-fluoroestradiol PET/CT

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Hoag Memorial Hospital Presbyterian

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The standard of care imaging of breast cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. 18F-fluoroestradiol (FES) is a novel PET tracer designed to detect estrogen receptors, which are often expressed in breast cancers. FES PET/CT may provide improved evaluation of metastases in patients with ER-positive breast cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer.
Ulaner GA, Silverstein M, Nangia C, Tetef M, et al · · 2024 · cited 15× · PMID 39058489 · DOI 10.1001/jamanetworkopen.2024.23435
Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
Goodman K, Abel MK, Lawhn-Heath C, Molina-Vega J, et al · · 2022 · cited 2× · PMID 36243494 · DOI 10.1016/j.soc.2022.06.001
Evaluating Automated Tools for Lesion Detection on <sup>18</sup>F Fluoroestradiol PET/CT Images and Assessment of Concordance with Standard-of-Care Imaging in Metastatic Breast Cancer.
Miller R, Battle M, Wangerin K, Huff DT, et al · · 2025 · cited 1× · PMID 40314583 · DOI 10.1148/rycan.240253

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Hoag Memorial Hospital Presbyterian trials

Trials by the same sponsor.

NCT06736054 — A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer · Phase 1 · recruiting
NCT05880394 — Study of Dotatate Imaging in Breast Cancer · Phase 2 · unknown
NCT04814615 — A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma · Phase 2 · unknown
NCT04700332 — PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer · Phase 2 · recruiting
NCT04750434 — PET MRI as a Staging Tool for Head and Neck Cancer · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04883814 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoag Memorial Hospital Presbyterian
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04883814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing